ALKERMES | ALKS - أرباح التشغيل





أرباح التشغيل تغيير تاريخ
AbbVie USD 6.88B 156M 2026-09
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
ALKERMES USD -65.93M 17.65M 2026-06
Amgen USD 4.61B 777M 2026-06
Biogen USD 419.5M 663.3M 2026-09
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Bristol-Myers Squibb USD 255M 44M 2026-09
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 12.46B 2.68B 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
J&J USD 6.47B 1B 2026-09
Malin Corporation EUR -1.1M 400K 2024-12
Merck USD 7.33B 6.49B 2026-09
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 343M 123.1M 2026-09
Otsuka Holdings JPY 142.24B 1.83B 2026-09
Ovoca Bio EUR -173K 990K 2025-12
Pfizer USD 662M 5M 2026-09
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Vertex Pharmaceuticals USD 1.26B 11.3M 2026-09